MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.

WEST CHESTER, Pa. & ISTANBUL — Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177Lu (n.c.a. 177Lu). Read More